Table 8. F-EVAR cohort clinical outcomes.
| Authors | MAE (major adverse events) | 30-day mortality | Cause of death | Over-30-day mortality | Cause of death | Patency (6 months) | Follow-up (months) | Length of stay (days) | Secondary intervention rate |
|---|---|---|---|---|---|---|---|---|---|
| Lee et al. 201438 | 2 MI; 1 stroke; | 0 | 2 | Not related to AAA | 96% | 6 | 4 (2–23) | 13.30% | |
| 3 Type IIand 1 Type III endoleaks; | |||||||||
| 1 RA occlusion | |||||||||
| Globalstar 201218 | 8 MI; 5 cardiac failure; 7 arrhythmia; 8 pneumonia; | 2 | Not related to AAA | 11 | Not related to AAA | 98% | 6 | 9 (1–100) | 10% (12 months) |
| 3 COPD; 5 GI ischemia;6 sepsis or septicemia; | |||||||||
| 9 wound complications; 3 TIA; 5 spinal ischemia; 3 lower limb ischemia; | |||||||||
| 17 Type I;22 Type II;5 Type III endoleaks; | |||||||||
| 2 RA perforation;1 RA stenosis; 4 RFI; 1 ARF; 11 RF;1 RA occlusion;3 Renal branch Bleeding; | |||||||||
| Liao et al. 201439 | 1 splenic embolization; | 0 | 2 | 1 C.O.P.D. + heart failure 1 bowel ischemia + M.O.F. | N.D. | 6.1 (2.7–8.3) | 3 (1–9) | 0 | |
| 2 Type IIendoleaks; 1 renal hematoma; | |||||||||
| Dijkstra et al. 201440 | 1 compartment syndrome left lower leg; 1 rupture of common iliac artery; 1 occluded SMA; 1 cutaneous bleeding; 1 hemorrhagic CVA; | 1 | M.O.F. | 1 | 1 stroke (6 months) | 96% (1 month) | 11 (1–29) | N.D. | 0 |
| 5 Type I, 12 Type II and 4 Type III endoleaks; | |||||||||
| 1 RFI; 1 RA occlusion | |||||||||
| Donas et al. 201231 | 1 occluded SMA; | 0 | N.D. | 97.7% | 13.2 ± 4.2 | 3.5 ± 1.1 | 3.4% | ||
| 3 Type I and 7 Type II endoleaks; | |||||||||
| 1 LRA occlusion | |||||||||
| Suominen et al. 201332 | 3 wound infection; 1 MI; 1 occluded common iliac artery; | 2 | 1 pneumonia 1 MI | 3 | 1 stroke (51 months) | N.D. | 22 (1–46) | N.D. | 10% (12 month) |
| 1 Type II endoleak; | 1 gastrointestinal bleeding (12 months) | ||||||||
| 1 RFI; 1 stent twist | 1 tumor (41 months) | ||||||||
| Greenberg et al. 200941 | 2 arrhythmia; 7 transfusions; 1 low extremite embolus; | 0 | 2 | not related to AAA (677 days) | 89% | 24 | 3.7 (1–8) | 17% | |
| 1 supplemental O2 ; 1 paralytic ileus; 1 wound infection 3 CHF; 1 arrhythmia; 1 pneumonia; 2 incisional hernia; | 1 MI (754 days) | 51/57 | |||||||
| 1 Type I, 1 Type II and 1 Type III endoleaks; | |||||||||
| 2 RFI; 4 RA stenosis; 2 RA occlusion | |||||||||
| Tambyraja et al. 201142 | 3 Iliac limb stenosis/occlusion; 1 SMA occlusion; | 0 | 4 | 1 stroke (22 months) | N.D. | 20 (7–62) | 3 (1–12) | 38% | |
| 2 Type I, 5 Type II and 2 Type III endoleaks; | 1 M.O.F. (18 months) | ||||||||
| 1 RA perforation; 9 RA stenosis; 2 RA occlusion; 3 stent migration | 1 pneumonia (15 months) | ||||||||
| 1 renal failure. (18 months) | |||||||||
| Oderich et al. 201443 | 3 bowel obstruction; 1 bowel obstruction; 1 stroke; 1 MI; 3 CHF; 2 cardiac ischemia; | 1 | Bowel ischemia (related to AAA) | 4 | 1 M.O.F. | 95% | 37 (3–65) | 3.3 ± 2.1 | 22% |
| 1 Type I and 16 Type IIendoleaks; | 2 M.I. | ||||||||
| 4 RA occlusion;12 RA stenosis; 8 RFI; 3 Renal failure | 2 unknown cause |
N.D. not documented; M.I. myocardial infarction; COPD, chronic obstructive pulmonary disease; M.O.F. multiple organ failure; RFI, renal function impairment; ARF, acute renal failure; RF, renal failure; RA, renal artery; SMA, superior mesenteric artery.